Manipulation of the intestinal microbiome-a slow journey to primetime
暂无分享,去创建一个
[1] A. Gasbarrini,et al. Fecal microbiota transplantation for recurrent C. difficile infection in patients with inflammatory bowel disease: A systematic review and meta-analysis. , 2023, Journal of autoimmunity.
[2] Xia Wu,et al. Colonic Transendoscopic Enteral Tubing Is a New Pathway to Microbial Therapy, Colonic Drainage, and Host–Microbiota Interaction Research , 2023, Journal of clinical medicine.
[3] T. Karlsen,et al. The microbiota and the gut–liver axis in primary sclerosing cholangitis , 2022, Nature Reviews Gastroenterology & Hepatology.
[4] G. Ianiro,et al. Evaluating microbial determinants of donor efficacy to translate faecal microbiota transplantation from research to clinical practice , 2022, Gut.
[5] P. Manghi,et al. Variability of strain engraftment and predictability of microbiome composition after fecal microbiota transplantation across different diseases , 2022, Nature Medicine.
[6] Peeyush Kumar,et al. Faecal microbiota transplantation with anti-inflammatory diet (FMT-AID) followed by anti-inflammatory diet alone is effective in inducing and maintaining remission over 1 year in mild to moderate ulcerative colitis: a randomised controlled trial , 2022, Gut.
[7] T. Borody,et al. Microbial determinants of effective donors in faecal microbiota transplantation for UC , 2022, Gut.
[8] Z. Deng,et al. Effect of Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial , 2022, Frontiers in Cellular and Infection Microbiology.
[9] Bo Jiang,et al. Efficacy and safety of fecal microbiota transplantation for the induction of remission in active ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials , 2022, Annals of translational medicine.
[10] Jana G Hashash,et al. Efficacy of Fecal Microbiota Transplantation in the Treatment of Active Ulcerative Colitis: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials. , 2022, Inflammatory bowel diseases.
[11] C. Pollock,et al. Faecal Microbiota Transplantation and Chronic Kidney Disease , 2022, Nutrients.
[12] O. Gilja,et al. Efficacy of fecal microbiota transplantation for patients with irritable bowel syndrome at three years after transplantation. , 2022, Gastroenterology.
[13] A. Weinberger,et al. Use of Faecal Transplantation with a Novel Diet for Mild to Moderate Active Ulcerative Colitis: The CRAFT UC Randomised Controlled Trial , 2021, Journal of Crohn's & colitis.
[14] L. Fu,et al. Gut Microbiota Dysbiosis as One Cause of Osteoporosis by Impairing Intestinal Barrier Function , 2021, Calcified Tissue International.
[15] S. Bel,et al. Diet-induced modifications to human microbiome reshape colonic homeostasis in irritable bowel syndrome , 2021, bioRxiv.
[16] T. Hausken,et al. Current status of fecal microbiota transplantation for irritable bowel syndrome , 2021, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.
[17] P. Hrabák,et al. Fecal Microbial Transplantation versus Mesalamine Enema for Treatment of Active Left-Sided Ulcerative Colitis—Results of a Randomized Controlled Trial , 2021, Journal of clinical medicine.
[18] K. Garey,et al. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[19] M. Surette,et al. Results of the first pilot randomized controlled trial of fecal microbiota transplant in pediatric ulcerative colitis: lessons, limitations, and future prospects. , 2021, Gastroenterology.
[20] H. Sokol,et al. Recipient factors in faecal microbiota transplantation: one stool does not fit all , 2021, Nature Reviews Gastroenterology & Hepatology.
[21] J. Allard,et al. Manipulation of intestinal microbiome as potential treatment for insulin resistance and type 2 diabetes , 2021, European Journal of Nutrition.
[22] E. Gomaa. Human gut microbiota/microbiome in health and diseases: a review , 2020, Antonie van Leeuwenhoek.
[23] A. Masclee,et al. Intestinal permeability in human nonalcoholic fatty liver disease: A systematic review and meta‐analysis , 2020, Liver international : official journal of the International Association for the Study of the Liver.
[24] Yun Han Kwon,et al. Mucins in Intestinal Mucosal Defense and Inflammation: Learning From Clinical and Experimental Studies , 2020, Frontiers in Immunology.
[25] C. McKenzie,et al. Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial. , 2020, The American journal of gastroenterology.
[26] V. Anttila,et al. Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome , 2020, Alimentary pharmacology & therapeutics.
[27] H. Sokol,et al. Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study , 2020, Microbiome.
[28] Bota Cui,et al. Efficacy of faecal microbiota transplantation in Crohn’s disease: a new target treatment? , 2020, Microbial biotechnology.
[29] Bota Cui,et al. Washed microbiota transplantation vs. manual fecal microbiota transplantation: clinical findings, animal studies and in vitro screening , 2020, Protein & Cell.
[30] O. Gilja,et al. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study , 2019, Gut.
[31] A. Hart,et al. Gaps in knowledge and future directions for the use of faecal microbiota transplant in the treatment of inflammatory bowel disease , 2019, Therapeutic advances in gastroenterology.
[32] E. Mazzon,et al. The Gut Microbiota in Multiple Sclerosis: An Overview of Clinical Trials , 2019, Cell transplantation.
[33] T. Hausken,et al. Diet in Irritable Bowel Syndrome (IBS): Interaction with Gut Microbiota and Gut Hormones , 2019, Nutrients.
[34] T. Grigoryeva,et al. Markers of dysbiosis in patients with ulcerative colitis and Crohn's disease. , 2019, Terapevticheskii arkhiv.
[35] W. D. de Vos,et al. The Effect of Allogenic Versus Autologous Fecal Microbiota Transfer on Symptoms, Visceral Perception and Fecal and Mucosal Microbiota in Irritable Bowel Syndrome: A Randomized Controlled Study , 2019, Clinical and translational gastroenterology.
[36] R. Finn,et al. A new genomic blueprint of the human gut microbiota , 2019, Nature.
[37] T. Vatanen,et al. The Super-Donor Phenomenon in Fecal Microbiota Transplantation , 2019, Front. Cell. Infect. Microbiol..
[38] I. Tentes,et al. Gut Microbial Signatures Underline Complicated Crohn's Disease but Vary Between Cohorts; An In Silico Approach. , 2018, Inflammatory bowel diseases.
[39] L. Hansen,et al. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study , 2018, Gut.
[40] D. Gerding,et al. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[41] Y. Naito,et al. Gut microbiota in the pathogenesis of inflammatory bowel disease , 2018, Clinical Journal of Gastroenterology.
[42] R. Xavier,et al. OP014 - Analysis of 1792 gut metagenomes reveals microbial treatment targets for inflammatory bowel disease and irritable bowel syndrome , 2018 .
[43] G. Kaplan,et al. Effect of Oral Capsule– vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent Clostridium difficile Infection: A Randomized Clinical Trial , 2017, JAMA.
[44] L. Albenberg,et al. Gut microbiota and IBD: causation or correlation? , 2017, Nature Reviews Gastroenterology &Hepatology.
[45] G. Latella,et al. Low-FODMAP Diet Improves Irritable Bowel Syndrome Symptoms: A Meta-Analysis , 2017, Nutrients.
[46] Yingwei Chen,et al. New Frontiers in Genetics, Gut Microbiota, and Immunity: A Rosetta Stone for the Pathogenesis of Inflammatory Bowel Disease , 2017, BioMed research international.
[47] J. Raes,et al. The resilience of the intestinal microbiota influences health and disease , 2017, Nature Reviews Microbiology.
[48] K. Whelan,et al. The low FODMAP diet: recent advances in understanding its mechanisms and efficacy in IBS , 2017, Gut.
[49] L. Öhman,et al. Multivariate modelling of faecal bacterial profiles of patients with IBS predicts responsiveness to a diet low in FODMAPs , 2017, Gut.
[50] T. Hausken,et al. Effects of varying dietary content of fermentable short‐chain carbohydrates on symptoms, fecal microenvironment, and cytokine profiles in patients with irritable bowel syndrome , 2017, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.
[51] Lisa M Bramer,et al. Dynamics of the human gut microbiome in Inflammatory Bowel Disease , 2017, Nature Microbiology.
[52] S. Bordenstein,et al. Fecal Transplants: What Is Being Transferred? , 2016, PLoS biology.
[53] Lin Chang,et al. Development and Validation of the Rome IV Diagnostic Questionnaire for Adults , 2016 .
[54] J. Raes,et al. Donor Species Richness Determines Faecal Microbiota Transplantation Success in Inflammatory Bowel Disease. , 2016, Journal of Crohn's & colitis.
[55] A. Keshteli,et al. FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial , 2016, Gut.
[56] C. Romano,et al. Inflammatory Bowel Disease: Genetics, Epigenetics, and Pathogenesis , 2015, Front. Immunol..
[57] R. D'Incà,et al. Intestinal Permeability in Inflammatory Bowel Disease: Pathogenesis, Clinical Evaluation, and Therapy of Leaky Gut , 2015, Mediators of inflammation.
[58] L. Cigliano,et al. Rescue of Fructose-Induced Metabolic Syndrome by Antibiotics or Faecal Transplantation in a Rat Model of Obesity , 2015, PloS one.
[59] O. Goulet. Potential role of the intestinal microbiota in programming health and disease. , 2015, Nutrition reviews.
[60] E. Zoetendal,et al. Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis. , 2015, Gastroenterology.
[61] L. Laine,et al. Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook. , 2015, Gastroenterology.
[62] M. Surette,et al. Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. , 2015, Gastroenterology.
[63] B. Jefferson,et al. The Characterization of Feces and Urine: A Review of the Literature to Inform Advanced Treatment Technology , 2015, Critical reviews in environmental science and technology.
[64] P. Gibson,et al. Diets that differ in their FODMAP content alter the colonic luminal microenvironment , 2014, Gut.
[65] K. Whelan,et al. Mechanisms and efficacy of dietary FODMAP restriction in IBS , 2014, Nature Reviews Gastroenterology &Hepatology.
[66] S. Rabot,et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice , 2012, Gut.
[67] E. Zoetendal,et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. , 2012, Gastroenterology.
[68] Derrick W. Crook,et al. Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[69] E. Goldstein,et al. Antimicrobial Activities of Fidaxomicin , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[70] M. Falagas,et al. Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. , 2012, International journal of antimicrobial agents.
[71] A. Ford,et al. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[72] Neil Stollman,et al. Long-Term Follow-Up of Colonoscopic Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection , 2012, The American Journal of Gastroenterology.
[73] S. Bischoff,et al. Nutrition, Intestinal Permeability, and Blood Ethanol Levels Are Altered in Patients with Nonalcoholic Fatty Liver Disease (NAFLD) , 2012, Digestive Diseases and Sciences.
[74] Richard A. Flavell,et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity , 2012, Nature.
[75] Judy H. Cho,et al. Recent insights into the genetics of inflammatory bowel disease. , 2011, Gastroenterology.
[76] Xiaojing Ma,et al. Role of Nod2 in the development of Crohn's disease. , 2009, Microbes and infection.
[77] Stuart Johnson. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. , 2009, The Journal of infection.
[78] S. Mazmanian,et al. The gut microbiota shapes intestinal immune responses during health and disease , 2009, Nature Reviews Immunology.
[79] M. Wilcox,et al. Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model. , 2009, The Journal of antimicrobial chemotherapy.
[80] R Balfour Sartor,et al. Microbial influences in inflammatory bowel diseases. , 2008, Gastroenterology.
[81] E. Purdom,et al. Diversity of the Human Intestinal Microbial Flora , 2005, Science.
[82] J. Hampe,et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease , 2004, Gut.
[83] P. Rutgeerts,et al. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum , 1991, The Lancet.
[84] J. Bennet,et al. TREATMENT OF ULCERATIVE COLITIS BY IMPLANTATION OF NORMAL COLONIC FLORA , 1989, The Lancet.
[85] D. Jewell,et al. Role of the faecal stream in the maintenance of Crohn's colitis. , 1985, Gut.
[86] A M Stephen,et al. The microbial contribution to human faecal mass. , 1980, Journal of medical microbiology.
[87] J. Bartlett,et al. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. , 1978, The New England journal of medicine.
[88] L. Brandt,et al. Should We Standardize the 1,700-Year-Old Fecal Microbiota Transplantation? , 2012, The American Journal of Gastroenterology.